Dihydropyrimidine deshydrogenase (DPD): Rhythm and consequences;Dihydropyrimidine déshydrogénase (DPD): Rythme et conséquences

Pathologie Biologie

Volumn 53, Issue 5, 2005, Pages 261-264

  Barrat Petit, M A ^a   Naulin Ifi, C ^d   Mahler, P ^b   Milano, G ^c  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b University Hospital of Nice University of Nice Sophia Antipolis   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

5 fluorouracil; Chronopharmacology; Circadian rhythm; Dihydropyrimidine deshydrogenase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID;

ARTICLE; CIRCADIAN RHYTHM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; LYMPHOCYTE; MOLECULAR INTERACTION; PERIPHERAL BLOOD MONONUCLEAR CELL;

BIOTRANSFORMATION; CIRCADIAN RHYTHM; DIHYDROURACIL DEHYDROGENASE (NADP); FLUOROURACIL; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR;

EID: 20444403412     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.12.031     Document Type: Article

References (30)

1. F. Ĺvi, N.A. Boughattas, and I. Blazsek Comparative chronotoxicity of anticancer agents and related mechanisms Ann. Rev. Chronopharmacol 4 1988 283 331
2. F. Ĺvi, R. Zidani, and J.L. Misset Randomised multicenter trial of chemotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer Lancet 350 1997 681 686
3. F. Levi, R. Zidani, and S. Brienza A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucivorin as initial treatment of patients with metastatic colorectal carcinoma Cancer 1999 2532 2540
4. F.N.M. Naguib, S.J. Soong, and M.H. El Khouny Circadian rhythm of orotate phosphoribosyltransferase, pyrimidine nucleoside phosphorylases, and dihydrouracil dehydrogenase in mouse liver Biochemical Pharmacology 45 3 1993 667 673
5. R. Zhang, Z. Lu, and T. Liu Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes:: possible relevance to fluoropyrimidine chemotherapy Cancer Res. 53 1993 2816 2822
6. M.H. El Khouny, F.N.M. Naguib, and K.S. Park Circadian rhythm of hepatic uridine phosphorylase activity and plasma concentration of uridine in mice Bioch. Pharmacol. 40 1990 2479 2485
7. R. Duschinsky, E. Pleven, and C. Heidelberger The synthesis of 5 fluoropyrimidines J. Am. Chem. Soc. 79 1957 4559 4560
8. B. Podschun, G. Wahler, and K.D. Schnackerz Purification and characterisation of dihydropyrimidine dehydrogenase from pig liver Eur. J. Biochem. 185 1989 219 224
9. Z.H. Lu, R. Zhang, and R.B. Diasio Purification and characterisation of dihydropyrimidine dehydrogenase from human liver J. Biol. Chem. 267 1992 17102 17109
10. F.N.M. Naguib, M.H. El Kouni, and S. Cha Enzymes of uracil catabolism in normal and neoplastic human tissues Cancer Res. 45 1985 5405 5412
11. B.E. Harris, R. Song, Y.J. He, and R. Diasio Circadian rhythm of rat liver dihydropyrimidine dehydrogenase:: possible relevance to fluoropyrimidine chemotherapy Bioch. Pharm. 37 24 1988 4759 4762
12. M. Chazal, M.C. Etienne, and N. Reńe Link between dihydropyrimidine deshydrogenase activity in peripheral blood mononuclear cells and liver Clin. Cancer Res. 2 1996 507 510
13. M.C. Etienne, J.L. Lagrange, and O. Dassonville Population study of dihydropyrimidine dehydrogenase in cancer patients J. Clin. Oncol. 12 1994 2248 2253
14. M. Tuchman, J.S. Stoeckeler, and D.T. Kiang Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity N. Engl. J. Med. 313 1985 245 249
15. P. Houyan, C. Gay, and E. Chatelut Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency J. Natl. Cancer Inst. 85 1993 1602 1603
16. R.B. Diasio, T.L. Beavers, and J.T. Carpenter Familial deficiency of dihydropyrimidine dehydrogenase J. Clin. Invest. 81 1988 47 57
17. B.E. Harris, J.T. Carpenter, and R.B. Diasio Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome Cancer 68 1991 499 501
18. R.A. Fleming, G.A. Milano, M.H. Gaspard, and P.J. Bargnoux Dihydropyrimidine dehydrogenase activity in cancer patients Eur. J. Cancer 29A 1993 740 744
19. G. Milano, M.C. Etienne, V. Pierrefite, M. Barberi-Heyob, R. Deporte-Fety, and N. Reńe Dihydropyrimidine dehydrogenase deficiency and fluorouracil related toxicity Br. J. Cancer 79 1999 627 630
20. Z. Lu, R. Zhang, and R.B. Diasio Dihydropyrimidine dehydrogenase blood mononuclear cells and liver:: population characteristics, newly identified deficients patients, and clinical implication in 5-fluorouracil chemotherapy Cancer Res. 53 1993 5433 5438
21. E. Petit, G. Milano, F. Ĺvi, A. Thyss, F. Bailleul, and M. Schneider Circadian varying plasma concentration of 5-FU during 5-day continuous venous infusion at constant rate in cancer patients Cancer Res. 48 1988 1676 1679
22. L. Thiberville, C. Compagnon, and N. Moore Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil Cancer Chemoth. Pharmacol 35 1994 64 70
23. G. Metzger, C. Massari, M.C. Etienne, M. Commisso, S. Brienza, and Y. Touitou Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in cancer patients Clin. Pharm. Ther 56 1994 190 201
24. G.F. Flemming, R.L. Schilsky, and R. Mick Circadian variation of 5-fluorouracil (5-FU) and cortisol plasma levels during continuous-infusion 5-FU and leucovorin (LV) in patients with hepatic or renal dysfunction Proc. Amer. Soc. Clin. Oncol. 13 abstr 1994 352
25. F. Bressole, J.M. Joulia, F. Pinguet, and M. Ychou Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer Cancer Chemother. Pharmacol. 44 1999 295 302
26. B. Harris, R. Song, S. Soong, and R.B. Diasio Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels: evidence for circadian variation of plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion Cancer Res. 50 1990 197 201
27. Langouët AM, Metzger G, Comisso M, Reńe N, Milano G, Mormont MC, et al. Plasma concentration of 5-fluorouracil and mononuclear cell dihydropyrimidine dehydrogenase activity in patients treated with different chronomodulated schedules. Proc. World Conference on Chronobiology and Chronotherapeutics, Ferrara, Italy, 1995, Biol. Rhythm Res., 1995, 26(4), 409 (abstr. 135).
28. A.B. Van Kuilenburg, R.L. Poorter, G.L. Peters, and A.H. Van Gennip No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil Adv. Exp. Med. Biol. 431 1998 811 816
29. M. Tuchman, R. Von Roemeling, R.M. Lanning, R.B. Sothern, and W.J.M. Hrushesky Sources of variability of dihydropyrimidine dehydrogenase activity in human blood mononuclear cells Ann. Rev. Chronopharmacol. 5 1988 399 402
30. J.L. Grem, L.K. Yee, D.J. Venzon, C.H. Takimoto, and C.J. Allegra Inter and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells Cancer Chemother. Pharmacol. 40 1997 117 125